BioPharma Credit (LSE:BPCR) Moat Score: 0/10 (As of Jul. 02, 2026)


LSE:BPCR BioPharma Credit PLC LSE:BPCR
49 GF Score
Price $0.96
GF Value $0.97
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit Moat Score?

BioPharma Credit has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

BioPharma Credit has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioPharma Credit might have No Moat - No discernible moat.

BioPharma Credit  (LSE:BPCR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioPharma Credit Moat Score Related Terms

LSE:BPCR
49GF Score
BioPharma Credit PLC LSE:BPCR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued. The current stock price of $0.96 is trading 1% below its estimated GF Value™ of $0.97. GuruFocus considers BioPharma Credit to be Fairly Valued.

Key valuation signals for LSE:BPCR:

  • Moat Score: 0
  • GF Value™: $0.97 vs. price of $0.96 (1% below fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
49GF Score

Get the complete analysis for LSE:BPCR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$0.97
GF Value